Risk averse reproduction numbers improve resurgence detection.


Journal

PLoS computational biology
ISSN: 1553-7358
Titre abrégé: PLoS Comput Biol
Pays: United States
ID NLM: 101238922

Informations de publication

Date de publication:
07 2023
Historique:
received: 10 12 2022
accepted: 06 07 2023
revised: 01 08 2023
medline: 2 8 2023
pubmed: 20 7 2023
entrez: 20 7 2023
Statut: epublish

Résumé

The effective reproduction number R is a prominent statistic for inferring the transmissibility of infectious diseases and effectiveness of interventions. R purportedly provides an easy-to-interpret threshold for deducing whether an epidemic will grow (R>1) or decline (R<1). We posit that this interpretation can be misleading and statistically overconfident when applied to infections accumulated from groups featuring heterogeneous dynamics. These groups may be delineated by geography, infectiousness or sociodemographic factors. In these settings, R implicitly weights the dynamics of the groups by their number of circulating infections. We find that this weighting can cause delayed detection of outbreak resurgence and premature signalling of epidemic control because it underrepresents the risks from highly transmissible groups. Applying E-optimal experimental design theory, we develop a weighting algorithm to minimise these issues, yielding the risk averse reproduction number E. Using simulations, analytic approaches and real-world COVID-19 data stratified at the city and district level, we show that E meaningfully summarises transmission dynamics across groups, balancing bias from the averaging underlying R with variance from directly using local group estimates. An E>1generates timely resurgence signals (upweighting risky groups), while an E<1ensures local outbreaks are under control. We propose E as an alternative to R for informing policy and assessing transmissibility at large scales (e.g., state-wide or nationally), where R is commonly computed but well-mixed or homogeneity assumptions break down.

Identifiants

pubmed: 37471464
doi: 10.1371/journal.pcbi.1011332
pii: PCOMPBIOL-D-22-01819
pmc: PMC10393178
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1011332

Subventions

Organisme : Medical Research Council
ID : MR/R015600/1
Pays : United Kingdom

Informations de copyright

Copyright: © 2023 Parag, Obolski. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

We declare no competing interests.

Références

Am J Epidemiol. 2006 Sep 15;164(6):591-7
pubmed: 16887892
Nature. 2021 Jan;589(7840):82-87
pubmed: 33171481
PLoS Comput Biol. 2021 Sep 7;17(9):e1009347
pubmed: 34492011
PLoS One. 2007 Aug 22;2(8):e758
pubmed: 17712406
J R Stat Soc Ser A Stat Soc. 2022 May 26;:
pubmed: 35942192
Nat Commun. 2021 Jan 12;12(1):323
pubmed: 33436609
Comput Math Methods Med. 2011;2011:527610
pubmed: 21860658
Sci Data. 2015 May 26;2:150019
pubmed: 26029377
Trends Ecol Evol. 2006 Jul;21(7):394-9
pubmed: 16815438
PLoS Comput Biol. 2014 Jul 10;10(7):e1003716
pubmed: 25010676
Nat Hum Behav. 2020 Sep;4(9):964-971
pubmed: 32759985
Proc Natl Acad Sci U S A. 2021 May 4;118(18):
pubmed: 33926962
Proc Natl Acad Sci U S A. 2005 Aug 9;102(32):11157-62
pubmed: 16055564
Syst Biol. 2020 Nov 1;69(6):1163-1179
pubmed: 32333789
Am J Epidemiol. 2004 Sep 15;160(6):509-16
pubmed: 15353409
Int Stat Rev. 2020 Aug;88(2):462-513
pubmed: 32834402
Nature. 2021 Dec;600(7887):127-132
pubmed: 34695837
Science. 2009 Jun 19;324(5934):1557-61
pubmed: 19433588
Proc Biol Sci. 2007 Feb 22;274(1609):505-12
pubmed: 17476770
Philos Trans R Soc Lond B Biol Sci. 2021 Jul 19;376(1829):20200282
pubmed: 34053258
J R Soc Interface. 2010 Jun 6;7(47):873-85
pubmed: 19892718
Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6146-51
pubmed: 15071187
PLoS Comput Biol. 2019 May 8;15(5):e1006917
pubmed: 31067217
Int J Infect Dis. 2020 Apr;93:284-286
pubmed: 32145466
PLoS Comput Biol. 2020 Dec 10;16(12):e1008409
pubmed: 33301457
Nature. 2001 Dec 13;414(6865):716-23
pubmed: 11742391
Science. 2020 Jul 10;369(6500):
pubmed: 32414780
Nat Rev Phys. 2022;4(1):12-13
pubmed: 34877474
Sci Transl Med. 2022 Jun;14(647):eabn9836
pubmed: 35412326
Sci Adv. 2020 Dec 4;6(49):
pubmed: 33158911
Syst Biol. 2019 Sep 1;68(5):730-743
pubmed: 30726979
J R Soc Interface. 2007 Oct 22;4(16):879-91
pubmed: 17640863
NPJ Digit Med. 2021 Apr 16;4(1):73
pubmed: 33864009
Nature. 2006 Jul 27;442(7101):448-52
pubmed: 16642006
Front Public Health. 2022 Sep 15;10:966756
pubmed: 36187701
Lancet Infect Dis. 2021 Feb;21(2):193-202
pubmed: 33729915
Lancet Infect Dis. 2019 Oct;19(10):1058-1059
pubmed: 31559960
Science. 2020 Sep 18;369(6510):1465-1470
pubmed: 32680881
PLoS Comput Biol. 2020 Jul 1;16(7):e1007990
pubmed: 32609732
N Engl J Med. 2014 Oct 16;371(16):1481-95
pubmed: 25244186
J R Soc Interface. 2005 Sep 22;2(4):295-307
pubmed: 16849187
Science. 2014 Jun 13;344(6189):1230-2
pubmed: 24926005
PLoS Comput Biol. 2022 Apr 11;18(4):e1010004
pubmed: 35404936
Lancet Digit Health. 2020 May;2(5):e218-e220
pubmed: 32518898
J R Soc Interface. 2011 Sep 7;8(62):1248-59
pubmed: 21345858
EClinicalMedicine. 2022 Sep 05;53:101620
pubmed: 36097540
PLoS One. 2011;6(5):e17835
pubmed: 21637342
Epidemics. 2015 Mar;10:63-7
pubmed: 25843386
Nature. 2021 May;593(7858):266-269
pubmed: 33767447
PLOS Glob Public Health. 2022 Nov 9;2(11):e0001211
pubmed: 36962648
Am J Epidemiol. 2013 Nov 1;178(9):1505-12
pubmed: 24043437
J R Soc Interface. 2022 Mar;19(188):20210429
pubmed: 35350879

Auteurs

Kris V Parag (KV)

MRC Centre for Global Infectious Disease Analysis, Imperial College London, London, United Kingdom.

Uri Obolski (U)

Department of Epidemiology and Preventive Medicine, School of Public Health, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Porter School of the Environment and Earth Sciences, Faculty of Exact Sciences, Tel Aviv University, Tel Aviv, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH